1. Pink Sheet
  2. >>R&D

Q&A: Janssen on where it is heading with real world evidence

 
• By Francesca Bruce

Getting to grips with real world evidence can help companies get their medicines to patients, but there are multiple challenges too, such as “messy” data and building trust, says Nigel Hughes of Janssen Pharmaceutical.

Patient medical record browse on tablet in someone hand on white background.

Real world evidence holds a lot of promise for companies. It could help make clinical research more efficient, saving time and money, and it could help prove the case for reimbursement and a better price. But making this potential a reality is not without difficulties. The data can be messy, sources are not joined up and there is a need to build up trust, according to Janssen Pharmaceuticals Inc's Nigel Hughes, scientific director of RMEDS (Real World Evidence, Medical Affairs, Established Products, Statistics). Hughes spoke to the Pink Sheet about the future of RWE and how Janssen is using it to enhance market access.

We gather our RWE globally, at a regional and local level and Janssen focuses on oncology, immunology, infectious disease and...

More from R&D

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Woodcock: Do Not Do The Wrong Study, Even If Against US FDA Advice

 
• By Sarah Karlin-Smith

The former CDER director said she tells sponsors not to conduct an FDA-recommended study design or randomized trial if it will not work.

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

UK Looks To Auto-Match NHS Patients With Clinical Trials To Boost Recruitment

 
• By Vibha Sharma

The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.

More from Pink Sheet

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 
• By Eliza Slawther

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

Global Guideline Signals ‘Paradigm Shift’ For Pregnant And Breastfeeding Women, Says EMA

 
• By Anabel Costa-Ferreira

The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges